1,25-dihydroxycholecalciferol in renal osteodystrophy. Epiphysiolysis--anticonvulsant therapy. 1977

A M Pierides, and H A Ellis, and H Dellagrammatikas, and J E Scott, and A W Norman

Three children with azotaemic renal osteodystrophy were treated with 1,25-dihydroxycholecalciferol (1,25(OH)2D3). All showed clinical, biochemical, and radiological improvement within 6 months of starting treatment. There were no complications. The dose of 1,25(OH)2D3 required was 0-5 microgram per day for 2 children aged 22 and 30 months, and 2 microgram per day for a 15-year-old boy. 2 of the patients were receiving phenobarbitone and phenytoin and in one of them prior treatment with dihydrotachysterol 0-5 mg daily and 6 microgram 1alpha-hydroxycholecalciferol (1alphaOHD3) daily had failed to induce improvement. In one patient, in whom serial iliac bone samples were available, 2 microgram 1,25(OH)2D3 resulted in histological improvement in previously severe osteomalacia. 1,25(OH)2D3 appears to be an effective and safe drug in the treatment of uraemic osteodystrophy.

UI MeSH Term Description Entries
D007223 Infant A child between 1 and 23 months of age. Infants
D008297 Male Males
D010634 Phenobarbital A barbituric acid derivative that acts as a nonselective central nervous system depressant. It potentiates GAMMA-AMINOBUTYRIC ACID action on GABA-A RECEPTORS, and modulates chloride currents through receptor channels. It also inhibits glutamate induced depolarizations. Phenemal,Phenobarbitone,Phenylbarbital,Gardenal,Hysteps,Luminal,Phenobarbital Sodium,Phenobarbital, Monosodium Salt,Phenylethylbarbituric Acid,Acid, Phenylethylbarbituric,Monosodium Salt Phenobarbital,Sodium, Phenobarbital
D010672 Phenytoin An anticonvulsant that is used to treat a wide variety of seizures. It is also an anti-arrhythmic and a muscle relaxant. The mechanism of therapeutic action is not clear, although several cellular actions have been described including effects on ion channels, active transport, and general membrane stabilization. The mechanism of its muscle relaxant effect appears to involve a reduction in the sensitivity of muscle spindles to stretch. Phenytoin has been proposed for several other therapeutic uses, but its use has been limited by its many adverse effects and interactions with other drugs. Diphenylhydantoin,Fenitoin,Phenhydan,5,5-Diphenylhydantoin,5,5-diphenylimidazolidine-2,4-dione,Antisacer,Difenin,Dihydan,Dilantin,Epamin,Epanutin,Hydantol,Phenytoin Sodium,Sodium Diphenylhydantoinate,Diphenylhydantoinate, Sodium
D012080 Chronic Kidney Disease-Mineral and Bone Disorder Decalcification of bone or abnormal bone development due to chronic KIDNEY DISEASES, in which 1,25-DIHYDROXYVITAMIN D3 synthesis by the kidneys is impaired, leading to reduced negative feedback on PARATHYROID HORMONE. The resulting SECONDARY HYPERPARATHYROIDISM eventually leads to bone disorders. Renal Osteodystrophy,Renal Rickets,Rickets, Renal,CKD-MBD,Osteodystrophy, Renal,Chronic Kidney Disease Mineral and Bone Disorder,Osteodystrophies, Renal,Renal Osteodystrophies
D001842 Bone and Bones A specialized CONNECTIVE TISSUE that is the main constituent of the SKELETON. The principal cellular component of bone is comprised of OSTEOBLASTS; OSTEOCYTES; and OSTEOCLASTS, while FIBRILLAR COLLAGENS and hydroxyapatite crystals form the BONE MATRIX. Bone Tissue,Bone and Bone,Bone,Bones,Bones and Bone,Bones and Bone Tissue,Bony Apophyses,Bony Apophysis,Condyle,Apophyses, Bony,Apophysis, Bony,Bone Tissues,Condyles,Tissue, Bone,Tissues, Bone
D002675 Child, Preschool A child between the ages of 2 and 5. Children, Preschool,Preschool Child,Preschool Children
D004100 Dihydroxycholecalciferols Cholecalciferols substituted with two hydroxy groups in any position. Dihydroxyvitamins D
D004839 Epiphyses, Slipped A complete or partial separation of the EPIPHYSES from the DIAPHYSES. Epiphysiolysis,Epiphysiolyses,Slipped Epiphyses
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

A M Pierides, and H A Ellis, and H Dellagrammatikas, and J E Scott, and A W Norman
March 1981, Canadian Medical Association journal,
A M Pierides, and H A Ellis, and H Dellagrammatikas, and J E Scott, and A W Norman
March 1978, Lancet (London, England),
A M Pierides, and H A Ellis, and H Dellagrammatikas, and J E Scott, and A W Norman
January 1980, Contributions to nephrology,
A M Pierides, and H A Ellis, and H Dellagrammatikas, and J E Scott, and A W Norman
October 1979, The American journal of medicine,
A M Pierides, and H A Ellis, and H Dellagrammatikas, and J E Scott, and A W Norman
January 1975, Canadian Medical Association journal,
A M Pierides, and H A Ellis, and H Dellagrammatikas, and J E Scott, and A W Norman
December 1979, Schweizerische medizinische Wochenschrift,
A M Pierides, and H A Ellis, and H Dellagrammatikas, and J E Scott, and A W Norman
January 1979, Proceedings of the European Dialysis and Transplant Association. European Dialysis and Transplant Association,
A M Pierides, and H A Ellis, and H Dellagrammatikas, and J E Scott, and A W Norman
May 1980, Klinische Wochenschrift,
A M Pierides, and H A Ellis, and H Dellagrammatikas, and J E Scott, and A W Norman
January 1983, Acta medica Scandinavica,
A M Pierides, and H A Ellis, and H Dellagrammatikas, and J E Scott, and A W Norman
January 1973, Proceedings of the European Dialysis and Transplant Association. European Dialysis and Transplant Association,
Copied contents to your clipboard!